TIDMSCLP

RNS Number : 9067V

Scancell Holdings Plc

06 December 2023

6 December 2023

Scancell Holdings plc

("Scancell" or the "Company")

PDMR Notification

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that further to the Company's announcement on the 1 December 2023 regarding the successful placing of ordinary shares of nominal value of 0.1 pence in the Company ("Shares") and the subscription for Shares by Dr Jean-Michel Cosséry and Professor Lindy Durrant, the following Shares were issued on 5 December 2023:

                      Dr Jean-Michel Cosséry                   454,545 
                      Professor Lindy Durrant                   272,727

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
       Details of the person discharging managerial responsibilities/person 
   1    closely associated 
 a)    Name                             Jean-Michel Cosséry 
      -------------------------------  --------------------------------------------- 
       Reason for the notification 
  2 
      ------------------------------------------------------------------------------ 
 a)    Position/status                  Chairman of Board and PDMR 
      -------------------------------  --------------------------------------------- 
 b)    Initial notification/Amendment   Initial notification 
      -------------------------------  --------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------ 
 a)    Name                             Scancell Holdings plc 
      -------------------------------  --------------------------------------------- 
 b)    LEI                              2138008RXEG856SNP666 
      -------------------------------  --------------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4     each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been 
        conducted 
      ------------------------------------------------------------------------------ 
 a)    Description of the               Ordinary shares 
        financial instrument, 
        type of instrument 
      -------------------------------  --------------------------------------------- 
 b)    Identification Code              GB00B63D3314 
      -------------------------------  --------------------------------------------- 
 c)    Nature of the transaction        Acquisition of ordinary shares 
      -------------------------------  --------------------------------------------- 
 
 d)    Price(s) and volume(s)           454,545 ordinary shares at GBP0.11 per share 
      -------------------------------  --------------------------------------------- 
 e)    Aggregated information 
        - Aggregated volume               N/A (single transaction) 
        - Price 
      -------------------------------  --------------------------------------------- 
 f)    Date of the transaction          5 December 2023 
      -------------------------------  --------------------------------------------- 
 g)    Place of the transaction         Outside a trading venue 
      -------------------------------  --------------------------------------------- 
 
 
       Details of the person discharging managerial responsibilities/person 
   1    closely associated 
 a)    Name                             Lindy Durant 
      -------------------------------  --------------------------------------------- 
       Reason for the notification 
  2 
      ------------------------------------------------------------------------------ 
 a)    Position/status                  Executive Director and PDMR 
      -------------------------------  --------------------------------------------- 
 b)    Initial notification/Amendment   Initial notification 
      -------------------------------  --------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------ 
 a)    Name                             Scancell Holdings plc 
      -------------------------------  --------------------------------------------- 
 b)    LEI                              2138008RXEG856SNP666 
      -------------------------------  --------------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4     each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been 
        conducted 
      ------------------------------------------------------------------------------ 
 a)    Description of the               Acquisition of ordinary shares 
        financial instrument, 
        type of instrument 
      -------------------------------  --------------------------------------------- 
 b)    Identification Code              GB00B63D3314 
      -------------------------------  --------------------------------------------- 
 c)    Nature of the transaction        Acquisition of ordinary shares 
      -------------------------------  --------------------------------------------- 
 
 d)    Price(s) and volume(s)           272,727 ordinary shares at GBP0.11 per share 
      -------------------------------  --------------------------------------------- 
 e)    Aggregated information 
        - Aggregated volume               N/A (single transaction) 
        - Price 
      -------------------------------  --------------------------------------------- 
 f)    Date of the transaction          5 December 2023 
      -------------------------------  --------------------------------------------- 
 g)    Place of the transaction         Outside a trading venue 
      -------------------------------  ---------------------------------------------

-ENDS-

 
 For further information, please contact: 
 
 Scancell Holdings plc                                   +44 (0) 20 3709 5700 
 Professor Lindy Durrant, CEO 
  Dr Jean-Michel Cosséry, Non-Executive Chairman 
 Stifel Nicolaus Europe Limited (Nominated Adviser 
  and Joint Broker)                                      +44 (0) 20 7710 7600 
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown 
  (Healthcare Investment Banking) 
 Nick Adams/Nick Harland (Corporate Broking) 
 Panmure Gordon (UK) Limited (Joint Broker)              +44 (0) 20 7886 2500 
 Freddy Crossley/Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 
 
 ICR Consilium                                 +44 (0) 20 3709 5700 
 Mary-Jane Elliott/Matthew Neal/Chris Welsh    scancell@consilium-comms.com

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope (R) and ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody (R) ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab(R) ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab (R) ).

For further information about Scancell, please visit: https://www.scancell.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHTFBTTMTJMBPJ

(END) Dow Jones Newswires

December 06, 2023 07:41 ET (12:41 GMT)

Scancell (AQSE:SCLP.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Scancell Charts.
Scancell (AQSE:SCLP.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Scancell Charts.